|
Units
|
Pattern I MS
|
Pattern II + III MS
|
Pattern II MS
|
Pattern III MS
|
AQP4-IgG+ NMO [48]
|
---|
QIgM > Qlim(IgM)
|
Patients
|
3/9 (33.3)
|
3/17 (17.6)
|
3/12 (25)
|
0/5 (0)
|
n.d.
|
QIgM > Qlim(IgM), LPs
|
Samples
|
3/16 (18.8)
|
5/30 (16.7)
|
5/20 (25)
|
0/10 (0)
|
13/96 (14%)
|
QIgM, all LPs
|
–
|
0.58 (0.26–1.5; 15)
|
0.65 (0.1–14.1; 26)
|
0.8 (0.1–14.1; 17)
|
0.6 (0.5–5.8; 9)
|
0.9 (0–40.5; 97)
|
QIgM, if positive
|
–
|
0.8 (0.58–1.5; 3)
|
9.8 (3.5–14.1; 5)
|
9.8 (3.5–14.1; 5)
|
n.a.
|
8.3 (1.2–40.5; 13)
|
IgMloc, all LPs
|
mg/L
|
0 (0–0.27; 16)
|
0 (0–9.24; 29)
|
0 (0–9.24; 19)
|
0 (0–0; 10)
|
0 (0–35.3; 95)
|
IgMloc, QIgM positives
|
mg/L
|
0.12 (0.05–0.27; 3)
|
6.41 (0.86–9.24; 5)
|
6.41 (0.86–9.24; 5)
|
n.a.
|
0.9 (0–35.3; 13)
|
IgMIF, all LPs
|
%
|
0 (0–0.12; 16)
|
0 (0–0.86; 30)
|
0 (0–0.86; 20)
|
0 (0–0; 10)
|
0 (0-95.8; 95)
|
IgMIF, QIgM positives
|
%
|
0.1 (0.09-0.12; 3)
|
0.71 (0.17–0.86; 5)
|
0.71 (0.17–0.86; 5)
|
n.a.
|
15.3 (2.3–95.8; 13)
|
IgM CSF, all LPs
|
mg/L
|
1 (0.4–3; 15)
|
1.05 (0.2–17.8; 26)
|
1.2 (0.2–17.8; 17)
|
0.9 (0.54–11; 9)
|
0.7 (0–36.9; 100)
|
IgM CSF, QIgM positives
|
mg/L
|
1.2 (0.42–3; 3)
|
9 (5.4–17.8; 5)
|
9 (5.4–17.8; 5)
|
n.a.
|
n.d.
|
IgM serum, all LPs
|
g/L
|
1.68 (0.56–3.75; 16)
|
1.6 (0.38–3.68; 29)
|
1.45 (0.38–3.68; 20)
|
1.7 (0.9–2.2; 9)
|
0.96 (0.13–2.85; 99)
|
IgM serum, QIgM positives
|
g/L
|
1.51 (0.72–2; 3)
|
1.1 (0.64–1.5; 5)
|
1.1 (0.64–1.5; 5)
|
n.a.
|
n.d.
|
QIgA > Qlim(IgA)
|
Patients
|
2/8 (25)
|
1/17 (5.9)
|
1/12 (8.3)
|
0/5 (0)
|
n.d.
|
QIgA > Qlim(IgA)
|
Samples
|
2/15 (13.3)
|
1/29 (3.4)
|
1/19 (5.3)
|
0/10 (0)
|
5/88 (6%)
|
QIgA, all LPs
|
–
|
1.77 (1.01–5.7; 13)
|
2.5 (0.82–9.1; 29)
|
2.4 (1–6.6; 19)
|
3.3 (0.82–9.1; 10)
|
2.1 (0–40.4; 88)
|
QIgA, if positive
|
–
|
3.22 (1.73–4.7; 2)
|
1 (1–1; 1)
|
1 (1–1; 1)
|
n.a.
|
5.1 (3.7–20.2; 5)
|
IgAloc, all LPs
|
mg/L
|
0 (0–3.72; 15)
|
0 (0–0.08; 29)
|
0 (0–0.08; 19)
|
0 (0–0; 10)
|
0 (0–3.2; 86)
|
IgAloc, QIgA positives
|
mg/L
|
2.015 (0.31–3.72; 2)
|
0.08 (0.08–0.08; 1)
|
0.08 (0.08–0.08; 1)
|
n.a.
|
0.3 (0.03–3.2; 5)
|
IgAIF, all LPs
|
%
|
0 (0–0.73; 15)
|
0 (0–0.08; 29)
|
0 (0–0.08; 19)
|
0 (0–0; 10)
|
0 (0–7.5; 86)
|
IgAIF, QIgA positives
|
%
|
0.425 (0.12–0.73; 2)
|
0.08 (0.08–0.08; 1)
|
0.08 (0.08–0.08; 1)
|
n.a.
|
5.6 (0.5–7.5; 5)
|
IgA CSF, all LPs
|
mg/L
|
2.7 (1.4–16.6; 13)
|
4.55 (0.24–19.9; 30)
|
3.45 (0.24–17.5; 20)
|
8.5 (3.1–19.9; 10)
|
4.7 (0–131; 95)
|
IgA CSF, QIgA positives
|
mg/L
|
3.79 (2.5–5.08; 2)
|
1.1 (1.1–1.1; 1)
|
1.1 (1.1–1.1; 1)
|
n.a.
|
n.d.
|
IgA serum, all LPs
|
g/L
|
1.53 (0.9–2.9; 15)
|
1.88 (0.53–3.8; 29)
|
1.55 (0.53–3; 19)
|
2.6 (1.2–3.8; 10)
|
0.96 (0.13–2.85; 99)
|
IgA serum, QIgA positives
|
g/L
|
1.26 (1.08–1.45; 2)
|
1.1 (1.1–1.1; 1)
|
1.1 (1.1–1.1; 1)
|
n.a.
|
n.d.
|
-
n.a. not applicable, n.d. no data
- Concentrations, ratios and fractions are reported as medians; range and total sample numbers examined are given in brackets